Sirna and Lilly Collaborate to Find RNAi-Based Cancer Therapeutics

Jan 27, 2004

NEW YORK, Jan. 27 (GenomeWeb News) - Sirna Therapeutics and Eli Lilly plan to develop RNAi therapeutics for cancer, the companies said today.

During the eighteen-month collaboration, the companies will test Sirna's small interfering RNAs against oncology targets from Lilly.

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.

Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.

A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.

In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.